Replies to post #45423 on Breakthrough Chemistry Inc (BKTH)

[I ll be back]

Now for the rest of the story.
This was posted back in August over on the GEVI site and now lines up with the recent PRs posted by Break.

So I was doing some DD on GEVI and If by chance they would face a Prior Art challenge to their MFB31 patents from another company that has manufactured and sold a similar blend (AF31) for 15 years.

Fast forward. GEVI just completed an uplisting after going through a 1:6 RS back in August.

Possible GEVI concerns:
Impact on Uplisting and Investor Confidence
- Valuation Risk: Patents often underpin a company’s valuation, especially in tech, biotech, or pharma. If key patents are disputed, investors may reassess the company’s future revenue potential.
- Market Reaction: News of a patent dispute can cause stock volatility. OTC markets are already sensitive to news; NYSE investors may be even more reactive.
- Due Diligence Red Flags: NYSE uplisting requires rigorous financial and legal vetting. A pending patent dispute could delay or derail the process if it’s deemed material.

I now have a better understanding as to why Break received an offer to purchase its patent.

When Break announced that the company had entered into a "Mutual Hold Harmless" agreement, it happened right as GEVI was in the middle of uplisting to the AMEX. The timing of that announcement must have been an “OH SHIT” moment for GEVI’s management, which explains the unusually quick closing date in Breaks recent announcement. Something we don't normally see.

For those who lack an understanding of how the game of chess is played. This was what we call a "check" move in the business world.

IMO, Break played this card at JUST the right moment in time. Now we have to wait and see what they do with these newly found funds.

Now you know the rest of the story!